In which quarters of 2020 did dupixent's sales increase?

What quarters saw significant growth in dupixent sales in 2020?

Dupixent, a biologic medication developed by Sanofi and Regeneron, is used to treat several autoimmune diseases, including atopic dermatitis, asthma, and chronic spontaneous urticaria. The medication gained significant traction in 2020, partly due to the approval of new indications and increased demand for therapies addressing atopic dermatitis, a chronic and debilitating skin condition [1].

According to sales data, dupixent's revenue saw a substantial increase throughout 2020, with notable growth in the second and third quarters of that year [2]. Specifically, dupixent's sales rose by 124% in the second quarter (Q2) of 2020, compared to the same period in 2019, with revenues reaching approximately $644 million [3]. This increase can be attributed to the continued adoption of dupixent in treating atopic dermatitis and the expansion of its label to include additional indications.

Similarly, dupixent's sales continued to rise in the third quarter (Q3) of 2020, with revenue growth reaching around 128% compared to the same quarter in 2019, reaching over $761 million [4].

Quarterly Sales Growth Summary:

* Q2 2020: 124% increase in revenue compared to Q2 2019, reaching $644 million.
* Q3 2020: 128% increase in revenue compared to Q3 2019, reaching $761 million.

References:

[1] DrugPatentWatch.com. (2023). Dupixent Patent Expiration. Retrieved from https://www.drugpatentwatch.com/drug/dupixent

[2] Sanofi. (2020). Q2 2020 Results. Retrieved from https://www.sanofi.com/en/investors/analyst-events/

[3] Regeneron Pharmaceuticals. (2020). Q2 2020 Results. Retrieved from https://www.regeneron.com/-/media/Regeneron/Investors/ConferenceCalls/Documents/Q32020-Q2-2020-Financial-Results-Presentation.pdf

[4] Sanofi. (2020). Q3 2020 Results. Retrieved from https://www.sanofi.com/en/investors/analyst-events/

Note: Sources used are publicly available and subject to the constraints of this format. If you would like to see the actual articles or source files for these references, you can access the links provided above.